Table 1.
Table 1. Baseline Patient Characteristics and Treatment Dosage Information
| |||||||
---|---|---|---|---|---|---|---|
Dose level | Dose of Veliparib | Age | Sex | Disease Stage | ECOG PS | BRCA Mutation | Founder |
0–2A | 58 (41–71) | 10 M 7 F | III–IV | 0–1 | N/A | N/A | |
| |||||||
0 | 20 mg BID | 70 | M | IV | 0 | BRCA1: 185delAG | Founder (AJ) |
0 | 62 | M | IV | 1 | BRCA2: 6174delT | Founder (AJ) | |
0 | 66 | M | IV | 1 | |||
| |||||||
1 | 40 mg BID | 60 | M | IV | 1 | ||
1 | 64 | M | IV | 1 | BRCA2: 6174delT | Founder (AJ) | |
1 | 57 | M | III | 1 | Unknown | Unknown | |
| |||||||
2 | 80 mg BID | 70 | F | IV | 1 | BRCA1: 2800delAA | N |
2 | 56 | F | IV | 1 | BRCA1: 187delAG | Founder (AJ) | |
2 | 58 | M | IV | 1 | BRCA2: 6174delT | Founder (AJ) | |
2 | 51 | F | IV | 0 | BRCA2: c.8177A>G | N | |
2 | 55 | M | IV | 1 | |||
2 | 50 | F | IV | 1 | BRCA1: 5385insC | Founder (AJ) | |
| |||||||
2A | 80 mg BID cont | 71 | F | III | 0 | ||
2A | 58 | M | IV | 1 | |||
2A | 50 | F | IV | 1 | BRCA2: D281N(1069G>A) | N | |
2A | 70 | M | IV | 1 | |||
2A | 41 | F | IV | 1 |
Fifteen patients had stage IV disease and 2 patients had stage III. One patient in dose level 1 had an unknown BRCA status, but was included in the BRCA− group. Gemcitabine is fixed at 600 mg/m2 IV and cisplatin is fixed at 25 mg/m2 IV.